Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

Cancer Statistics, 2003

Ahmedin Jemal, Thomas S. Murray, Alicia Samuels et al. · CA A Cancer Journal for Clinicians · 2003 · 3.3K citations · Full text

Medicine, Demography, Oncology +17

Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer

Lois B. Travis, Eric J. Holowaty, Kjell Bergfeldt et al. · New England Journal of Medicine · 1999 · 359 citations · Full text

Medicine, Gynecology, Oncology +14

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Lloyd R. Kelland, G Abel, Mark J. McKeage et al. · PubMed · 1993 · 224 citations

Medicine, Oncology, Pharmacology +7

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

K. N., Martin Gleave, Richard Klasa et al. · PubMed · 2001 · 192 citations

Medicine, Oncology, Pharmacology +17

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer

William Kevin Kelly, Tracy Curley, Susan F. Slovin et al. · Journal of Clinical Oncology · 2001 · 183 citations

Medicine, Oncology, Pharmacology +17